Hai Xi Pharma (02637) will delay its listing.
(02637) announced that additional time is needed to finalize the announcement of the results of the additional issue and to obtain regulatory approval...
HaiXi Pharmaceuticals (02637) announced that the schedule for its listing will be postponed due to the need for additional time to finalize the announcement of the results of the allocation and obtain regulatory approval. The board of directors will provide the market with the latest information as soon as practically feasible.
Related Articles
Increased customer trading volumes help drive performance for Interactive Brokers Group, Inc. Class A (IBKR.US) Q3 revenue and EPS exceed expectations.
CMSC: It is expected that the price of gold will continue to reach new highs in the future.
Zhongtai: The growth rate of M1 in September continues to increase, and it is expected that financial funds will flow back at the end of the quarter.
Increased customer trading volumes help drive performance for Interactive Brokers Group, Inc. Class A (IBKR.US) Q3 revenue and EPS exceed expectations.
CMSC: It is expected that the price of gold will continue to reach new highs in the future.
Zhongtai: The growth rate of M1 in September continues to increase, and it is expected that financial funds will flow back at the end of the quarter.
RECOMMEND
